Clinical Trial

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Name: RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) — clinical trial record (NCT07492316)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PNOC020 rMB

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-29

Trial Details

NCT Number	NCT07492316
Lead Sponsor	University of Florida Collaborators: Pediatric Neuro-Oncology Consortium
Conditions	Recurrent Medulloblastoma
Enrollment	24 participants
Start Date	2026-04-24
Primary Completion	2030-09-01 (estimated)
Study Completion	2031-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-29